chronic rhinosinusitis
Conditions
Interventions
nasal spray group:Recombinant human basic fibroblast growth factor 70 000 IU was added to the bilateral surgical cavity filler after FESS, and again at the 14 days
Control group:The bilateral nasal cavity of patients after FESS was filled routinely and treated postoperatively
nasal drip group:Recombinant human basic fibroblast growth factor 70 000 IU was added to the bilateral surgical cavity filler after FESS, and again at the 14 days
Sponsors
The First Affliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A total of 60 patients with bilateral chronic sinusitis were selected (the diagnosis of chronic sinusitis was based on EPOS 2012 and CPOS diagnostic criteria). The difference of CT score and endoscopy score between the two sides of patients with chronic sinusitis was not more than 1 point, the total score was not more than 2 points; the age was more than 8 years old and less than 75 years old. FEV1 > 60% predicted value can tolerate general anesthesia operation. Subjects must volunteer to participate in the study and comply with the research requirements, agree to the operation, understand and follow-up plan, and correctly record scale scores, medication times, concomitant medication and adverse events.
Exclusion criteria
Exclusion criteria: 1. There are the following diseases: cystic fibrosis, congenital ciliary dyskinesia, nasal tumors or other obstructive injuries, large area of nasal bone hyperplasia, large area of nasal polyps (sinus polyps), invasive or non-invasive fungal sinusitis; 2. There are serious metabolic, cardiovascular, immune, neurological, blood, digestive, cerebrovascular or respiratory diseases in clinic, or any disease that the researchers consider to interfere with the evaluation of the results of the study or affect the safety of the subjects; 3. Currently participating in other clinical studies or other clinical researchers within 30 days, or staff directly involved in the study; 4. Psychiatric history, antagonistic personality, bad motivation, suspicion or other emotional or intellectual problems may affect the effectiveness of informed participation in the study; 5. Pregnant or lactating women; 6. Drug allergy to basic fibroblast growth factor (rh-bFGF), glucocorticoid and mucosal discharge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nasal symptom VAS score;Sinusitis Quality of Life Scale(SNOT-20);Sinus CT Lund-Mackey score;nasal endoscopy Lund-Kennedy score;Epithelial thickness of nasal mucosa;Number of cilia in nasal mucosa epithelium;Frequency of epithelial oscillation of nasal mucosa; | — |
Countries
China
Contacts
Public ContactJian-Bo Shi
The First Affliated Hospital of Sun Yat-Sen University
Outcome results
None listed